PDGFB and B-cell non-Hodgkin lymphoma: There have been some successful attempts to alter the propensity of MuLV for T-cell lymphomas by using an EμMyc transgenic mouse, which results in predominantly B-cell lymphomas [231], and by expressing platelet derived growth factor B-chain (PDGFβ) from an MuLV-based retrovirus to generate mice with glioblastomas, which require activation of PDGF receptors for tumourigenesis [219].